Clinical Trial Details
| Trial ID: | L4809 |
| Source ID: | NCT01499108 |
| Associated Drug: | Liraglutide |
| Title: | Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes |
| Acronym: | Liratime |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes |
| Interventions: | DRUG: liraglutide |
| Outcome Measures: | Primary: Change in ambulatory blood pressure, Change in 24h BP from day 1 to day 49 (baseline to end of treatment) and time to statistically significant change in BP 24h after initiation of or increased dose of liraglutide, 50 days | Secondary: Change in ECV, Changes in ECV (measured by GFR), urinary sodium, weight, arterial stiffness and daily home-BP, from day 1 to day 49 (baseline to end of treatment)., 50 days|Washout analysis, Change in 24h BP, ECV, weight, arterial stiffness from day 49 to day 70th, 21 |
| Sponsor/Collaborators: | Sponsor: Peter Rossing | Collaborators: Novo Nordisk A/S |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 32 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2012-08 |
| Completion Date: | 2014-08 |
| Results First Posted: | |
| Last Update Posted: | 2015-02-02 |
| Locations: | Steno Diabetes Center, Gentofte, 2820, Denmark |
| URL: | https://clinicaltrials.gov/show/NCT01499108 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|